cognitive cybersecurity intelligence

News and Analysis


Biosimilar Insulins Promise Patients New Choices, But Competition Is Still Lacking

Insulin spending topped $22bn in 2022 and its costs have tripled in the last decade, with major producers following last year’s Inflation Reduction Act and setting a $35 cap on out-of-pocket expenditure. Despite big three firms dominating the market with cheaper versions of branded products, new alternatives are emerging, such as Civica Rx, a nonprofit planning $30 per-vial insulin by 2024, and the state-run CalRx scheme that’s focusing first on insulin.

Source: –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts